Nuclear cardiology has a wide range of techniques that permit the accurate assessment of perfusion, metabolism, sympathetic innervation, and mechanical function of the heart.

Scintigraphic techniques of the heart include:
See also Echocardiography and Cardiovascular Imaging.

A perfusion scintigraphy records the organ blood circulation usually directly or during the first two minutes after the injection of a radioactive tracer.
Different types of radiopharmaceuticals are used, depending on the target organ.

Typical perfusion scans include:
See also First Pass Scintigraphy, Myocardial Scintigraphy, Heart Scintigraphy, Whole Body Scintigraphy, and Flare Phenomenon.

(GBPS) The gated blood pool scintigraphy is an examination to evaluate the ventricular performance. This scintigraphic blood pool imaging uses an electrocardiographic synchronizer or gating device to acquire data during repeated heart cycles at specific times in the heart cycle. Radionuclides, for example 99mTc-humanserumalbumin (HSA), are used as intravascular tracers.
GBPS allows to determinate the left ventricular function with heart minute volume, ejection fraction (EF) at rest and under exercise. Single photon emission computed tomography (SPECT) versus planar scintigraphic imaging improves cardiac evaluation due to the three dimensional nature. The GBPS method is not suitable to analyze the right ventricular function; that is best evaluated by first-pass ventriculography.
Echocardiography vs. GBPS has important disadvantages due to problems in quantitative evaluation, in patients with anatomic variations and dyskinetic left ventricles.

See also Myocardial Perfusion Imaging.

(MPI) The myocardial perfusion scan is the most common nuclear medicine procedure in cardiac imaging and allows assessing the blood-flow patterns to the heart muscles. The comparison of the radiopharmaceutical distribution after stress and at rest provides information on myocardial viability and cardiac perfusion abnormalities. ECG-gated myocardial perfusion imaging allows the assessment of global and regional myocardial function such as wall motion abnormalities.
The diagnostic accuracy of myocardial perfusion scintigraphy (also abbreviated MPS) allows reliable risk stratification and guides the selection of patients for further interventions, such as revascularization. MPI also has particular advantages over alternative techniques in the management of a number of patient subgroups, including women, the elderly, and those with diabetes. The use of this type of cardiac scintigraphy is associated with greater cost effectiveness of treatment, in terms of life-years saved, particularly in these special patient groups.
Myocardial perfusion scintigrams are acquired with a gamma camera. Single photon emission computed tomography (SPECT) is preferred over planar imaging because of the three dimensional nature of the images and their superior contrast resolution.
Common MPI radiopharmaceuticals, approved by the U.S. Food and Drug Administration (FDA) include: Tl-201 and the Tc-99m-labeled radiopharmaceuticals, such as sestamibi, tetrofosmin, and teboroxime for single-photon imaging. Rb-82 is used for positron emission tomography (PET) imaging.

See also Gated Blood Pool Scintigraphy, Myocardial Late Enhancement, Cardiac MRI and Echocardiography.

See Myocardial Perfusion Imaging.
Myocardial scintigraphy is a nuclear cardiology method for the diagnosis of various forms of heart disease.

See also Myocardial Late Enhancement, Cardiac MRI and Echocardiography.